PMID- 37789020
OWN - NLM
STAT- MEDLINE
DCOM- 20231005
LR  - 20231121
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 13
IP  - 1
DP  - 2023 Oct 3
TI  - Serum anti-phospholipase A2 receptor antibody in pathological diagnosis of type 2 
      diabetes mellitus patients with proteinuria.
PG  - 16608
LID - 10.1038/s41598-023-43766-8 [doi]
LID - 16608
AB  - Patients with diabetes mellitus complicated with proteinuria can be diabetic 
      nephropathy (DN), diabetic complicated with non-diabetic kidney disease (NDKD), 
      or DN with NDKD. Among these membranous nephropathy accounted for a large 
      proportion of DN with NDRD. At present, serum anti-phospholipase A2 receptor 
      (PLA2R) antibody is widely used in the diagnosis and evaluation of therapy in 
      idiopathic membranous nephropathy, our study aimed to investigate the diagnostic 
      significance of anti-PLA2R antibody in type 2 diabetes mellitus (T2DM) patients 
      with proteinuria, providing a method for patients with contraindications of 
      kidney biopsy. Eighty-seven T2DM patients with proteinuria who went on kidney 
      biopsy were divided into the DN group, idiopathic membranous nephropathy (IMN) 
      group, and others group according to their pathological results. In our study, 
      52.87% and 28.74% of patients were found to have IMN and diabetic nephropathy 
      respectively. The levels of anti-PLA2R antibody, total cholesterol, triglyceride, 
      and estimated glomerular filtration rate (eGFR) were higher in the IMN group, 
      while the prevalence of diabetic retinopathy (DR), systolic blood pressure (SBP) 
      and HbA1c were higher in the DN group. For T2DM patients with proteinuria, 
      anti-PLA2R antibody (AUC = 0.904, 95%CI 0.838-0.970) has a high diagnostic value 
      for IMN. The duration of diabetes (OR = 0.798, P = 0.030), eGFR level 
      (OR = 1.030, P = 0.024), and positive anti-PLA2R antibody (OR = 72.727, 
      P < 0.001) favor the diagnosis of IMN, while DR (OR = 50.234, P < 0.001), SBP 
      (OR = 1.041, P = 0.030), and negative anti-PLA2R antibody (OR = 0.008, 
      P  = 0.001) is beneficial to the diagnosis of DN. Our study found that NDKD is 
      not uncommon in patients with T2DM and proteinuria, and IMN was the main 
      pathological type. Positive anti-PLA2R antibody has a strong accuracy in the 
      diagnosis of IMN in patients with T2DM and proteinuria.
CI  - (c) 2023. Springer Nature Limited.
FAU - Zhang, Huanhuan
AU  - Zhang H
AD  - Department of Nephrology, Hebei General Hospital, Shijiazhuang, 050000, China.
FAU - Zhu, Yuanjie
AU  - Zhu Y
AD  - Department of Nephrology, Hebei General Hospital, Shijiazhuang, 050000, China.
FAU - Hu, Zhijuan
AU  - Hu Z
AD  - Department of Nephrology, Hebei General Hospital, Shijiazhuang, 050000, China. 
      huzhijuan1972@163.com.
FAU - Liu, Qiong
AU  - Liu Q
AD  - Department of Nephrology, Hebei General Hospital, Shijiazhuang, 050000, China.
LA  - eng
PT  - Journal Article
DEP - 20231003
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Receptors, Phospholipase A2)
SB  - IM
MH  - Humans
MH  - *Glomerulonephritis, Membranous/diagnosis
MH  - *Diabetes Mellitus, Type 2/complications
MH  - *Diabetic Nephropathies/diagnosis
MH  - Receptors, Phospholipase A2
MH  - Proteinuria/diagnosis
PMC - PMC10547755
COIS- The authors declare no competing interests.
EDAT- 2023/10/04 00:42
MHDA- 2023/10/05 06:43
PMCR- 2023/10/03
CRDT- 2023/10/03 23:20
PHST- 2023/06/05 00:00 [received]
PHST- 2023/09/28 00:00 [accepted]
PHST- 2023/10/05 06:43 [medline]
PHST- 2023/10/04 00:42 [pubmed]
PHST- 2023/10/03 23:20 [entrez]
PHST- 2023/10/03 00:00 [pmc-release]
AID - 10.1038/s41598-023-43766-8 [pii]
AID - 43766 [pii]
AID - 10.1038/s41598-023-43766-8 [doi]
PST - epublish
SO  - Sci Rep. 2023 Oct 3;13(1):16608. doi: 10.1038/s41598-023-43766-8.